Main Session: Best Practices in the Management of Infectious Complications for Patients with Cancer

How do biosimilars differ from generic drugs?

James S. Lewis, PharmD, FIDSA
Oregon Health and Science University

Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here